Second Sight Medical Products Inc (EYES)

[BluSkies]

Second Sight to Discuss Third Quarter 2017 Financial Results on November 2, 2017 Conference Call

EYES currently @ $1.08 PPS

Second Sight Medical Products, Inc. EYES has been given a $5.00 target price by HC Wainwright in a research report issued to clients and investors on Tuesday. The firm presently has a “buy” rating on the medical device company’s stock. HC Wainwright’s price target suggests a potential upside of 331.03% from the stock’s previous close.

EYES last issued its quarterly earnings data on Tuesday, August 1st. The medical device company reported ($0.13) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.14) by $0.01. Second Sight Medical Products had a negative return on equity of 168.49% and a negative net margin of 646.89%. The firm had revenue of $2.24 million during the quarter, compared to the consensus estimate of $1.43 million. During the same quarter in the previous year, the company posted ($0.17) EPS. The business’s revenue for the quarter was up 124.0% compared to the same quarter last year. On average, equities research analysts predict that Second Sight Medical Products will post ($0.55) earnings per share for the current year.


13.1% of Second Sight Medical Products shares are held by institutional investors
50.9% of Second Sight Medical Products shares are held by insiders. 13.1% of Second Sight Medical Products shares are held by institutional investors
50.9% of Second Sight Medical Products shares are held by insiders.